Log in to search using one of your social media accounts:


BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn(R) in ALS

Trial supported by a $16M non-dilutive grant from CIRM Top-line data are expected in 2019 HACKENSACK, N.J. and PETACH TIKVA, Israel, Oct. 16, 2017 -- (Healthcare Sales &Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today an... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

More News: ALS | Brain | Grants | Israel Health | Marketing | Middle East Health | Neurology | Pharmaceuticals | Stem Cell Therapy | Stem Cells